À propos Consynance therapeutics, inc.

À propos de la société

ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. ConSynance’s pipeline includes innovative treatments for non-alcoholic steatohepatitis (NASH), the orphan disease Prader-Willi Syndrome (PWS), and irritable bowel syndrome (IBS). ​ They believe that these assets have major competitive advantage over existing or in-development agents. These investigational therapeutics are the output of several years of previous drug discovery efforts at Albany Molecular Research, Inc (AMRI). The founders of ConSynance Therapeutics, Inc. were on the leadership team at AMRI during this effort and have licensed these assets into ConSynance as a vehicle for accelerating their development.